STUDIES ON HYPERPHOSPHATEMIA INDUCED BY DISODIUM ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE (EHDP) IN MAN

STUDIES ON HYPERPHOSPHATEMIA INDUCED BY DISODIUM ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE (EHDP) IN MAN

Opis bibliograficzny
Główni autorzy:	Walton, R, Russell, R, Alberti, K, Clark, M, Potts, J, Bisaz, S, Fleisch, H
Format:	Journal article
Język:	English
Wydane:	1974

Podobne zapisy

Proceedings: Some effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium metabolism in man.
od: Walton, R, i wsp.
Wydane: (1974)

Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man.
od: Walton, R, i wsp.
Wydane: (1975)

Effects of a diphosphonate (disodium etidronate: EHDP) on phosphate metabolism in Paget's disease of bone, primary hyperparathyroidism and type I hypophosphataemic rickets.
od: Walton, R, i wsp.
Wydane: (1976)

RESPONSE OF THE BONE AND KIDNEY TO EHDP IN MAN
od: Russell, R, i wsp.
Wydane: (1979)

Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.
od: Smith, R, i wsp.
Wydane: (1973)

Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.
od: Russell, R, i wsp.
Wydane: (1975)

ABNORMAL RESPONSES TO EHDP TREATMENT OF PAGETS-DISEASE
od: Smith, R, i wsp.
Wydane: (1977)

Diphosphonates in Paget's disease.
od: Russell, R, i wsp.
Wydane: (1974)

Diphosphonates and polyphosphates in medicine
od: Russell, R
Wydane: (1975)

Synthesis of Four Enantiomers of (1-Amino-3-Hydroxypropane-1,3-Diyl)Diphosphonic Acid as Diphosphonate Analogues of 4-Hydroxyglutamic Acid
od: Liwia Lebelt, i wsp.
Wydane: (2022-04-01)

Microstructure and Phase Characterization of Alkali-Activated Slag–Fly Ash Materials with Tetrasodium of 1-Hydroxy Ethylidene-1, 1-Diphosphonic Acid (HEDP·4Na)
od: Bo Zhou, i wsp.
Wydane: (2024-05-01)

Treatment of myositis ossificans progressiva with a diphosphonate.
od: Russell, R, i wsp.
Wydane: (1972)

Complexation of 1-Hydroxyethylidene-1,1-Diphosphonic Acid (HEDP) and Manganese(II) in Aqueous Solution
od: О.V. Bogatyrev, i wsp.
Wydane: (2016-03-01)

Proceedings: Background to the use of diphosphonates as bone scanning agents.
od: Russell, R, i wsp.
Wydane: (1975)

Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
od: Gray, R, i wsp.
Wydane: (1987)

Treatment of [99mTc]Tc‐hydroxy‐diphosphonate ([99mTc]Tc‐HDP) extravasation using hyaluronidase
od: Kevin R. Doornhof, i wsp.
Wydane: (2024-08-01)

The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats
od: Russell, R, i wsp.
Wydane: (1970)

Diaquabis{[1-hydroxy-2-(1H-imidazol-3-ium-1-yl)ethane-1,1-diyl]bis(hydrogen phosphonato)}manganese(II)
od: Yu Zhang, i wsp.
Wydane: (2009-12-01)

1-(5-Hydroxy-7-methoxy-2,2-dimethyl-2H-chromen-6-yl)ethan-1-one
od: Bingjing Liu, i wsp.
Wydane: (2010-06-01)

catena-Poly[zinc(II)-&#956;3-{hydrogen [1-hydroxy-2-(3-pyridinio)ethane-1,1-diyl]diphosphonato}]
od: Xihe Huang, i wsp.
Wydane: (2010-01-01)

Impact and mechanism of bisphosphonate depressant 1-hydroxypropane-1,1-diphosphonic acid on flotation decalcification of dolomite-rich magnesite ore
od: Wengang Liu, i wsp.
Wydane: (2024-07-01)

1-Phenyl-1-[(1-phenylethyl)sulfonylmethylsulfonyl]ethane
od: Jing-tao Liu, i wsp.
Wydane: (2009-12-01)

Hyperphosphatemia and Cardiovascular Disease
od: Chao Zhou, i wsp.
Wydane: (2021-03-01)

Phosphonoformic acid reduces hyperphosphatemia-induced vascular calcification via Pit-1
od: Hualong Zang, i wsp.
Wydane: (2024-01-01)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
od: Ju-Young Moon, i wsp.
Wydane: (2015-03-01)

Synthesis and structure of heterometallic multiligand Ge(IV) - 3d-metals complexes with 1-hydroxyethane-1,1-diphosphonic acid and 1,10-phenanthroline
od: Kyrylo Tsymbaliuk, i wsp.
Wydane: (2024-12-01)

Crystal structure of 1-(6-hydroxy-2-phenylbenzofuran-5-yl)ethan-1-one, C16H12O3
od: Olomola Temitope O., i wsp.
Wydane: (2020-10-01)

1-(Pyrrolidin-1-yl)ethan-1-iminium chloride
od: Rylan Artis, i wsp.
Wydane: (2023-09-01)

Disodium 4,5,6-trihydroxybenzene-1,3-disulfonate dihydrate
od: U. Beginn, i wsp.
Wydane: (2010-10-01)

Crystal structure of 1-(4-chloro-2-hydroxy-5-iodophenyl)ethan-1-one, C8H6ClIO2
od: Mphahlele Malose J.
Wydane: (2019-12-01)

Crystal structure of (E)-1-(2-hydroxy-3-{[2-hydroxybenzylidene]amino}phenyl)ethan-1-one, C15H13NO3
od: Yang Yu-Hua, i wsp.
Wydane: (2017-11-01)

Clinical Characteristics and Outcomes of Hyperphosphatemia in Patients with Chronic Kidney Disease Stages 1–2
od: Chao Xie, i wsp.
Wydane: (2024-07-01)

Reduction of skeletal blood flow in Paget's disease with disodium etidronate therapy
od: Walton, K, i wsp.
Wydane: (1985)

Hyperphosphatemia in chronic kidney disease
od: S. A. Martynov, i wsp.
Wydane: (2019-10-01)

Optimizing 1-hydroxyethylidene-1,1-diphosphonic acid and mechanically-activated iron ore tailings to prepare low-cost and retarded magnesium oxysulfate cement
od: Huihui Liang, i wsp.
Wydane: (2022-12-01)

New amino bisphosphonate compound for skeletal imaging: Comparison study with methylenediphosphonic acid (MDP) and (1-hydroxyethane-1,1-diyl) diphosphonic acid (HEDP)
od: Assaad Thaer
Wydane: (2016-03-01)

3,3′-[(1E,1′E)-Hydrazine-1,2-diylidenebis(ethan-1-yl-1-ylidene)]bis(4-hydroxy-6-methyl-2H-pyran-2-one)
od: Abouelhaoul El Alami, i wsp.
Wydane: (2019-10-01)

(E)-1-(4-Bromophenyl)ethan-1-one semicarbazone
od: Hoong-Kun Fun, i wsp.
Wydane: (2009-07-01)

(E)-1-(4-Fluorophenyl)ethan-1-one semicarbazone
od: Hoong-Kun Fun, i wsp.
Wydane: (2009-07-01)

Preparation of anti-reversion agent disodium hexamethylene-1,6-dithiosulfate dihydrate
od: LI Tian-yu1, HOU Wen-jie2, SHI Yun-hai1, YU Tao1
Wydane: (2024-01-01)